Published in Clin J Am Soc Nephrol on February 14, 2013
Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. Elife (2015) 1.41
Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol (2016) 0.81
IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol (2014) 0.79
The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation. J Pathol Clin Res (2016) 0.75
Characterization of glomerular extracellular matrix by proteomic analysis of laser captured microdissected glomeruli. Kidney Int (2016) 0.75
PLA2R and THSD7A: Disparate Paths to the Same Disease? J Am Soc Nephrol (2017) 0.75
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis (1993) 2.69
Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int (2003) 2.47
Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol (1990) 1.57
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol (2007) 1.36
Nephrotic syndrome associated with amyloid-like glomerular deposits. Nephron (1977) 1.33
Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol (2011) 1.29
Immunotactoid glomerulopathy. J Am Soc Nephrol (2002) 1.24
Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int (2002) 1.18
Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol (2010) 1.10
Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med (2010) 1.08
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet (2005) 4.09
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med (2012) 2.67
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol (2004) 2.53
Plasmablastic lymphoma and related disorders. Am J Clin Pathol (2011) 2.44
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum (2012) 1.99
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol (2011) 1.92
Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood (2005) 1.91
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood (2012) 1.75
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest (2012) 1.74
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood (2003) 1.73
Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int (2004) 1.71
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology (2004) 1.65
Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology (2008) 1.63
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol (2008) 1.61
Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med (2006) 1.61
Calcium dependence of polycystin-2 channel activity is modulated by phosphorylation at Ser812. J Biol Chem (2004) 1.60
Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 1.60
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit Care (2014) 1.57
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int (2011) 1.56
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid (2011) 1.55
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell (2012) 1.54
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma (2008) 1.54
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Validation of the Oxford classification of IgA nephropathy. Kidney Int (2011) 1.53
Plasma cell myeloma and related neoplasms. Am J Clin Pathol (2011) 1.52
Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol (2010) 1.52
Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol (2012) 1.51
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood (2014) 1.50
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol (2011) 1.46
Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis (2004) 1.46
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol (2013) 1.46
Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol (2010) 1.45
Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int (2003) 1.45